

Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site

- **Dr. Alexander Pelzer appointed as new Head of Research & Development, BRAIN Biotech Zwingenberg site**
- **Dr. Martin Langer takes on additional responsibility as Managing Director BioScience Operations, Zwingenberg**

Zwingenberg, Germany, 9 January 2023 – Biotechnology and enzyme expert BRAIN Biotech AG today announces the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology, the Group's management is now pleased to announce that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics.

Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path.

In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.

Adriaan Moelker, CEO of BRAIN Group, says: "I am very happy to promote Alexander to this important position. The fact that we were able to find an optimal successor for Michael Krohn within our company testifies to the development capabilities of our own professionals. Alexander comes with an excellent technical background. He also has the necessary experience in discovery, enzyme and strain optimization, fermentation, expression and scale-up to further drive the expansion of our enzymes and microorganisms business. Martin will be a strong leader

of the Zwingenberg team and continue to drive the growth of our TMS business. With these appointments, we are taking an important next step in our journey to become a provider of integrated solutions for our customers."

Press images:



Dr. Alexander Pelzer becomes Head of Research & Development at BRAIN Biotech site in Zwingenberg. © BRAIN Biotech AG



Dr. Martin Langer assumes responsibility as Managing Director and Executive Vice President BioScience Operations, Zwingenberg. © BRAIN Biotech AG

About BRAIN Biotech

BRAIN Biotech AG is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN's broad cutting-edge biotech expertise and its agile teams are key to success. - BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group. - As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. BRAIN Biotech's products and services target at least five of the UN SDGs directly. - Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-86
Email: ms@brain-biotech.com

Follow @BRAINbiotech on Twitter (<https://twitter.com/BRAINbiotech>) and @BRAIN Biotech AG on LinkedIn (<https://www.linkedin.com/company/brainbiotech>)

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.